首页> 外文期刊>American Journal of Pathology >Loss of Retinoic Acid Receptor-{beta} Expression Is an Early Event during Esophageal Carcinogenesis
【24h】

Loss of Retinoic Acid Receptor-{beta} Expression Is an Early Event during Esophageal Carcinogenesis

机译:维甲酸受体-β表达的丧失是食管癌变过程中的早期事件。

获取原文
获取原文并翻译 | 示例
           

摘要

We recently observed that growth inhibition of esophageal cancer cells by retinoic acid (RA) was associated with both constitutive expression and RA-induced up-regulation of RA receptor ß (RAR-ß). Cell lines that did not express RAR-ß were also resistant to RA. To explore the expression of RAR-ß mRNA in vivo, we analyzed esophageal tissue specimens from 16 normal mucosae, 30 dysplastic lesions, and 157 esophageal tumors by in situ hybridization. RAR-ß was detected in 88% (14/16) of normal esophageal tissues and in 96% (96/100) of distant normal esophageal mucosa from cancer specimens. In contrast, RAR-ß was expressed in only 57% (17/30) of dysplastic lesions and in 54% (84/157) of carcinomas. Among esophageal carcinomas RAR-ß mRNA was expressed in 62% (26/42) of well-differentiated, 54% (27/50) of moderately differentiated, and only 29% (4/14) of poorly differentiated SCCs. Our data suggest that the loss of RAR-ß expression is an early event associated with esophageal carcinogenesis and the status of squamous differentiation.
机译:我们最近观察到,视黄酸(RA)抑制食管癌细胞 的生长与本构表达和RA诱导的RA受体ß(RAR- ß)。不表达RAR-ß的Cell 系也对 RA具有抗性。为了探讨RAR-ßmRNA在体内的表达,我们通过原位杂交对16例正常黏膜,30例增生性病变和157例食管肿瘤中的食管组织标本进行了分析。 sup> 在正常食管组织中有88%(14/16)和远处正常食管粘膜中有96%(96/100)检测到RAR-ß >摘自癌症标本。相比之下,RAR-ß仅在增生异常病变的57%(17/30)和54%(84/157) 的癌症中表达。在食管癌中,RAR-ßmRNA 在分化良好的细胞中占62%(26/42),在中等分化的 中占54%(27/50),仅29 %(4/14)的低分化 SCC。我们的数据表明,RAR-ß表达的丧失 是与食管癌变和 鳞状细胞分化状态有关的早期事件。

著录项

  • 来源
    《American Journal of Pathology》 |1999年第5期|00001519-00001523|共5页
  • 作者单位

    From the Departments of Clinical Cancer Prevention,University of Texas M. D. Anderson Cancer Center, Houston, Texas;

    and the Center Laboratory for Tumor Biology,Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, China;

    and Pathology,University of Texas M. D. Anderson Cancer Center, Houston, Texas;

    From the Departments of Clinical Cancer Prevention,University of Texas M. D. Anderson Cancer Center, Houston, Texas;

    and the Center Laboratory for Tumor Biology,Cancer Institute and Hospital, Chinese Academy of Medical Science, Beijing, China;

    Thoracic/Head and Neck Medical Oncology,University of Texas M. D. Anderson Cancer Center, Houston, Texas;

    From the Departments of Clinical Cancer Prevention,University of Texas M. D. Anderson Cancer Center, Houston, Texas;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号